Answers are grounded in this paper and cite their sources.
Randomized trial compares the effects of topical tofacitinib and tacrolimus in localized vitiligo, highlighting efficacy and tolerability.
Background Topical ruxolitinib was recently approved by the US FDA for vitiligo. Studies comparing other topical Janus kinase inhibitors with established topical therapies like tacrolimus are lacking. Objectives To compare the efficacy and tolerability of topical tofacitinib and topical tacrolimus in patients with localized vitiligo using patient-reported and investigator-reported outcome measures. Methods Prospective, randomized, investigator-blinded, intraindividual, single-center comparative trial conducted over 16 weeks between January 2024 and December 2024. Thirty patients with 60 symmetrical vitiligo patches were enrolled. Eligible participants had slowly spreading, non-segmental vitiligo affecting ≤5% of body surface area. Patches were randomized to receive either topical tofacitinib (2%) ointment or topical tacrolimus (0.1%) ointment twice daily for 16 weeks. The primary outcome was percentage of patches achieving treatment success, defined as a Vitiligo Noticeability Scale (VNS) score of 4 (‘a lot less noticeable’) or 5 (‘no longer noticeable’). Secondary outcomes included time to treatment success, trends of VNS among groups, extent of repigmentation, and adverse effects. Results In tofacitinib group, 46.7% of patches achieved treatment success, compared to 36.7% in the tacrolimus group (p=0.601). The median time to treatment success was shorter for tofacitinib (8 weeks; 95% CI: 4.333–11.667) compared to tacrolimus (12 weeks; 95% CI: 8.301–15.699, p=0.176). Both groups showed significant repigmentation, with 33.3% of tofacitinib-treated patches and 20% of tacrolimus-treated patches achieving >80% repigmentation. Adverse events were fewer with tofacitinib (n=2) than tacrolimus (n=7). Facial lesions responded better than acral or trunk lesions in both groups. Conclusions Topical tofacitinib demonstrated comparable efficacy to tacrolimus for localized vitiligo but showed trends toward earlier patient-reported response and a more favourable safety profile, a finding that could be validated in future studies with larger sample size. Trial registration Clinical Trial Registry of India (CTRI/2023/12/060431)
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: